ClinicalTrials.gg
Active, not recruitingNCT06985147Updated Nov 2, 2026

A Phase 2, Open-Label Study of DISC-3405 in Participants With Polycythemia Vera (PV)

A Phase 2 interventional study of DISC-3405 in Polycythemia Vera (PV), sponsored by Disc Medicine, Inc. Active, not recruiting at 15 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by Disc Medicine, Inc · Phase 2, Interventional, and Treatment

Updated Nov 2, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
60
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 179 studies in Polycythemia Vera with a site in United States — 22 open to participants now, 34 under way, 7 of them phase 3. Polycythemia Vera · United States.

Planned enrollment
56th of 150
60 · median 40
Started
2025
with 3 others
Phase 2
68 of 179
7 open now
Primary completion
2027-07
later than 16 of 33 live
Registered
170th of 179
by date

Among the 179 studies in Polycythemia Vera with a site in United States, this one is the 56th largest by planned enrollment of the 150 interventional ones that give a count, is one of 4 that started in 2025, is one of 68 in phase 2, reaches primary completion later than 16 of the 33 other live ones, and was the 170th registered.

Polycythemia Vera

279 studies on the registry are indexed under Polycythemia Vera; 54 are open to participants now.

Browse Polycythemia Vera studies →

Open to participants now

22 of the 179 studies in Polycythemia Vera with a site in United States are open now. Recruiting first, the newest first:

17 more — sign in →

All 22 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 43 Polycythemia Vera studies recruiting now, 39 (91%) set no upper age limit and 1 (2%) stops at 75 or younger; 4 take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 179 studies in Polycythemia Vera with a site in United States, or all of them as a file.
02

Study summary

This open-label, multicenter, within-participant dose escalation study examining up to 2 dose levels of DISC-3405 will assess the safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of DISC-3405 in participants with polycythemia vera (PV).

03

Conditions studied

  • Polycythemia Vera (PV)

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged 18 years or older at the time of signing the form (ICF).
  2. Meet revised 2022 World Health Organization (WHO) criteria for the diagnosis of PV.
  3. Complete blood count values at Screening of HCT \<45% or HCT \<48% if followed by a phlebotomy within 2 weeks, white blood cells 4000/μL to 20,000/μL (inclusive), and 100,000/μL to 1,000,000/μL (inclusive).
  4. At least 3 phlebotomies in 26 weeks before Screening or at least 5 phlebotomies in 52 weeks before Screening. At least 1 phlebotomy must be within the 12 weeks prior to Screening.
  5. Participants receiving cytoreductive therapy must have been taking for at least 6 months and be on a stable PV therapy regimen for at least 2 months for hydroxyurea, interferon or ruxolitinib with no anticipated need for dose adjustments during the study, or have decreasing dose (with medical monitor approval).
  6. Participants treated with phlebotomy alone must have stopped cytoreductive therapy 6 months before Screening.
  7. (ECOG) performance status 0 or 1, or with medical monitor approval, ECOG 2.
  8. If male with female sexual partner(s) of , agrees to use one of the following acceptable methods of during the study and for at least 120 days after the last study drug dose:

    1. Stable hormonal contraceptive (≥3 months; female partner) in conjunction with a barrier method (eg, condom or diaphragm [female partner])
    2. Intrauterine device in place for at least 3 months (female partner)
    3. Surgically sterile hysterectomy, bilateral oophorectomy, or bilateral tubal ligation (female partner) in conjunction with a barrier method (eg, condom [male or female] or diaphragm)
    4. Confirmed successful vasectomy in conjunction with a barrier method (eg, condom [male or female] or diaphragm)
  9. If female, then EITHER , defined as at least 12 months of natural, spontaneous amenorrhea, 6 months of spontaneous amenorrhea with serum follicle-stimulating hormone >40 mIU/mL at Screening, or at least 6 weeks following surgical menopause (bilateral oophorectomy with or without hysterectomy); surgically sterile, OR agreeable to use of highly effective contraception (listed below) on Day 1 (or earlier) and for at least 120 days after the last dose of study drug:

    1. Stable hormonal contraceptive (≥3 months) in conjunction with a barrier method (eg, condom [male or female] or diaphragm)
    2. Intrauterine device in place for at least 3 months
    3. Tubal ligation or single male partner with vasectomy in conjunction with a barrier method (eg, condom [male or female] or diaphragm)
  10. Negative pregnancy test (females of childbearing potential).
  11. Able to understand the study aims, procedures, and requirements, and provide written informed consent.
  12. Able to comply with all study procedures.

Exclusion criteria

Exclusion Criteria:

  1. laboratory abnormalities at Screening.
  2. Participants who require phlebotomy at HCT levels \<45%.
  3. Clinically significant thrombosis (eg, deep vein thrombosis or splenic vein thrombosis) within 2 months prior to study treatment.
  4. Clinically significant active or chronic bleeding, considered meaningful in consultation with the medical monitor, within 6 months prior to study treatment.
  5. Significant renal dysfunction, evidenced by estimated of \<30 mL/min/1.73 m2 at the Screening visit, as assessed locally.
  6. History of invasive within the last 5 years, except localized cured prostate cancer and cervical cancer, or other malignancies deemed acceptable by the Sponsor.
  7. Participants with in situ or stage 1 squamous cell carcinoma of the skin, in situ or stage 1 basal cell carcinoma of the skin, or in situ melanoma of the skin identified during Screening unless the cancer is adequately treated before study entry.
  8. Received busulfan, pipobroman, or phosphorus-32 within 7 months prior to Screening.
  9. Major surgery within 8 weeks before Screening or incomplete recovery from any previous surgery.
  10. A history or known allergic reaction to any product or history of anaphylaxis to any food or drug.
  11. History of alcohol dependence or excessive alcohol consumption, as assessed by the Investigator.
  12. Active (HIV), or C. A positive hepatitis or HIV result should be discussed between the Investigator and Sponsor prior to enrollment.
  13. Other medical or psychiatric condition or laboratory finding not specifically noted above that, in the judgment of the Investigator or Sponsor, would put the participant at unacceptable risk or otherwise preclude the participant from participating in the study.
  14. Condition or concomitant medication that would confound the ability to interpret clinical data, including a major psychiatric condition that has had an exacerbation or required hospitalization in the last 6 months.
  15. If female, pregnant or breastfeeding.
  16. Participation in any other clinical protocol or investigational study that involves administration of experimental therapy and/or therapeutic devices within 30 days (or 5 half-lives for drugs, whichever is longer) of Screening. Previous use of other hepcidin inducing agents that may impact TMPRSS6 expression are not allowed. Previous use of hepcidin mimetics may be allowed in discussion with the Sponsor.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Within-participant dose escalation

    This is an open-label, multicenter, within-participant dose escalation study examining up to 2 dose levels of DISC-3405.

    Drug: DISC-3405

Interventions

  • DISC-3405 is administered subcutaneously.

06

What researchers measure

Primary outcomes

  1. Number of participants with treatment-related adverse events as assessed by CTCAE

    Proportion of participants with treatment-emergent adverse events

    Time frame: Up to 365 days

  2. Incidence of clinically abnormal vital signs

    Proportion of participants with changes in vital signs

    Time frame: Up to 365 days

  3. Incidence of clinically abnormal physical exam

    Proportion of participants with changes in physical examinations

    Time frame: Up to 365 days

  4. Incidence of clinically abnormal electrocardiograms

    Proportion of participants with changes in electrocardiograms (ECGs)

    Time frame: Up to 365 days

  5. Incidence of abnormal laboratory test results

    Proportion of participants with changes in clinical laboratory results

    Time frame: Up to 365 days

Secondary outcomes

  1. Proportion of participants achieving therapeutic response, defined as absence of phlebotomy eligibility, during the maintenance period

    Time frame: Up to 365 days

  2. Number of phlebotomies during the maintenance and optimization periods

    Time frame: Up to 365 days

  3. Proportion of participants achieving therapeutic response, defined as absence of phlebotomy eligibility, during the optimization period

    Time frame: Up to 365 days

  4. Proportion of participants with HCT values <45% throughout the study

    Time frame: Up to 365 days

  5. Area under the plasma concentration versus time curve (AUC) following the first dose

    Time frame: Up to 365 days

  6. Peak plasma concentration (Cmax) following the first dose

    Time frame: Up to 365 days

  7. Elimination half-life (t½el) following the first dose

    Time frame: Up to 365 days

  8. Apparent clearance (CL/F) following the first dose

    Time frame: Up to 365 days

  9. Maximum concentration at steady state (Cmax_ss) after repeating doses

    Time frame: Up to 365 days

  10. Pre-dose trough concentration (Ctrough) after repeating doses

    Time frame: Up to 365 days

  11. Change from baseline for HCT

    Time frame: Up to 365 days

  12. Change from baseline for serum hepcidin-25

    Time frame: Up to 365 days

  13. Change from baseline for serum iron

    Time frame: Up to 365 days

  14. Apparent volume of distribution (Vd/F)

    Time frame: Up to 365 days

07

Study locations

15 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for Jul 2027, 23 months after the start.

Of 44 phase 2 interventional studies under Polycythemia Vera, half reached primary completion within 81 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 135. This study's planned 23 months is below that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 2, 2026: primary completion Feb 2027 → Jul 2027 and completion Feb 2029 → Jul 2029.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 7, 2025
First posted
May 22, 2025
StartActual
Aug 12, 2025
Primary completionEst.
Jul 2027was Feb 2027
CompletionEst.
Jul 2029was Feb 2029
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Feb 2027→Jul 2027
Nov 2, 2026
Study completion
Feb 2029→Jul 2029
Nov 2, 2026
Show all 1 update
  1. Nov 2, 2026
    Primary completion Feb 2027→Jul 2027
    Study completion Feb 2029→Jul 2029
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06985147
Lead sponsor
Disc Medicine, Inc
Responsible party
Sponsor
First posted
May 22, 2025
Start date
Aug 12, 2025
Primary completion
Jul 2027 (estimated)
Completion
Jul 2029 (estimated)
Last update
Nov 2, 2026

Study contacts

Will Savage, MD PhD
study director · Disc Medicine

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anti-TMPRSS6 Monoclonal Antibody DISC-3405

Start the discussion